Company Filing History:
Years Active: 2023
Title: The Innovative Contributions of Jeffrey Khoo
Introduction
Jeffrey Khoo is a notable inventor based in Singapore, recognized for his significant contributions to the field of antiviral research. His work focuses on developing effective treatments for viral infections, particularly those caused by coronaviruses.
Latest Patents
Khoo holds a patent for "Terameprocol and nordihydroguaiaretic acid (NDGA) derivatives as coronavirus anti-viral agents." This patent highlights the utility of NDGA derivatives, including terameprocol (TMP), as antiviral agents for patients infected with or at risk of infection from coronaviruses, including SARS-CoV-2. In vitro studies demonstrate that coronavirus-infected cells treated with concentrations of 0.2 μM-20 μM TMP exhibit reduced viral RNA activity. Notably, treatment-related cytotoxicity is not observed at 0.2 μM TMP, with minimal cytotoxicity at 5 μM TMP. The application of these NDGA derivatives may involve intravenous administration at a molar concentration of 0.1-50 μM or oral administration at a molar concentration of 0.1-100 μM.
Career Highlights
Khoo's career is marked by his dedication to advancing antiviral therapies. His innovative approach to utilizing NDGA derivatives has positioned him as a key figure in the fight against viral infections. His research has the potential to significantly impact patient care and treatment outcomes.
Collaborations
Khoo collaborates with Stephan D Glenn, further enhancing the research and development of antiviral agents. Their combined expertise contributes to the advancement of effective treatments for viral infections.
Conclusion
Jeffrey Khoo's work exemplifies the spirit of innovation in the field of antiviral research. His contributions, particularly through his patent on NDGA derivatives, hold promise for improving treatment options for patients facing viral infections.